360° SearchNetwork Hot Spots Trends Time Series

Martin Mackay

Type: Person

Name: Martin Mackay

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Alexion Pharmaceuticals announces management changes

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, has appointed Martin Mackay as executive vice president, global head of R&D, and Saqib Islam as senior vice president, chief strategy and portfolio officer, and promoted Stephen Squinto as executive ... [Published Individual.com - May 07 2013]

Entities: Alexion Pharmaceuticals Inc, Martin Mackay, Leonard Bell, Research & Development

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Hartford Financial Services Group Inc

Alexion Profits Jump In First Quarter, New Executives Join Company

(The Hartford Courant - McClatchy-Tribune Information Services via COMTEX News Network) -- Alexion Pharmaceuticals Inc., which will begin construction on a new headquarters in New Haven in June, today posted first quarter profits of $82.2 million, or ... [Published PredictWallStreet - Apr 25 2013]

Entities: Alexion Pharmaceuticals Inc, Hartford Financial Services Group Inc, Eculizumab

First reported Apr 25 2013 - Updated Apr 25 2013 - 3 reports

Alexion Adds to Exec Team

Related Searches: Manufacturing • Bio News & Views • • Development •Related Breaking NewsAlexion Pharmaceuticals has expanded its executive leadership team through several appointments and promotions. Stephen Squinto, Ph.D., co-founder of Alexion, is ... [Published Contract Pharma - Apr 25 2013]

Entities: Alexion Pharmaceuticals Inc, Martin Mackay, Leonard Bell

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Global Operations

Less Than 5% of Global Firms Have Internal Mobile Strategy Teams, Say IDC and Netbiscuits

LONDON - (BUSINESS WIRE) - Netbiscuits, the global leader in software solutions for adaptive web experiences, today launched a whitepaper commissioned from IDC entitled "Best Practice for Mobility Centres of Excellence." With 98% of future IT growth ... [Published NewsBlaze - Apr 25 2013]

Entities: Netbiscuits, Doctor of Philosophy, Martin Mackay, Global Operations, Alexion Pharmaceuticals Inc

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

MarineMax Inc

MarineMax Reports Second Quarter Fiscal 2013 Results

CLEARWATER, Fla. - (BUSINESS WIRE) - MarineMax, Inc. (NYSE: HZO), the nation's largest recreational boat retailer, today announced results for its second fiscal quarter ended March 31, 2013.Revenue grew 11% to $160.0 million for the quarter ended March ... [Published NewsBlaze - Apr 25 2013]

Entities: MarineMax Inc, Doctor of Philosophy, World Acceptance Corporation, Martin Mackay

First reported Jan 15 2013 - Updated Jan 16 2013 - 2 reports

AstraZeneca PLC

How Will AstraZeneca Fare With These Losses?

Britain’s second-largest pharmaceutical company, AstraZeneca ( NYSE:AZN ), will face its second large shake-up in two months, with the exit of two top officials from the company . Shake-up 1 AstraZeneca faced the first shake-up in early December ... [Published Wall St. Cheat Sheet - Jan 15 2013]

Entities: AstraZeneca PLC, Research & Development, Patent

First reported Jan 15 2013 - Updated Jan 15 2013 - 2 reports

AstraZeneca Shuffles Pack

AstraZeneca said the company's head of research and development, Martin Mackay, is leaving the company amid a senior-management shake-up by new Chief Executive Pascal Soriot. ... [Published WSJ.com: What's News Asia - Jan 15 2013]

Entities: AstraZeneca PLC, Martin Mackay, Pascal Soriot

First reported Jan 15 2013 - Updated Jan 15 2013 - 1 reports

AstraZeneca Shakeup

And while we're talking big pharma shakeups, I note that AstraZeneca's new CEO has rearranged the executive furniture pretty vigorously , ditching Martin Mackay. He was the R&D head, ex-Pfizer, and seems to have lasted about two years at AZ, whose well-known ... [Published In the Pipeline - Jan 15 2013]

Entities: AstraZeneca PLC, Martin Mackay, Ditching

Quotes

"i am excited to be joining alexion at a time when the company is developing the most robust pipeline in its history. with an exclusive focus on transformative therapies, we can bring hope to an increasing number of patients with a wide range of life-threatening ultra-rare disorders" said Dr Mackay

Alexion Pharmaceuticals announces management changes [Published Individual.com - May 07 2013]

More Content

sort by: Date \| Relevance
Alexion Pharmaceuticals announces management ch... [Published Individual.com - May 07 2013]
Alexion Profits Jump In First Quarter, New Exec... [Published PredictWallStreet - Apr 25 2013]
Alexion Adds to Exec Team [Published Contract Pharma - Apr 25 2013]
Less Than 5% of Global Firms Have Internal Mobi... [Published NewsBlaze - Apr 25 2013]
MarineMax Reports Second Quarter Fiscal 2013 Re... [Published NewsBlaze - Apr 25 2013]
Alexion Broadens and Strengthens its Executive ... [Published NewsBlaze - Apr 25 2013]
Alexion Broadens and Strengthens its Executive ... [Published BioPortfolio - Apr 25 2013]
How Will AstraZeneca Fare With These Losses? [Published Wall St. Cheat Sheet - Jan 15 2013]
Pascal Soriot rings the changes in AZ [Published PharmaGossip - Jan 15 2013]
AstraZeneca Shuffles Pack [Published WSJ.com: What's News Asia - Jan 15 2013]
AstraZeneca Shuffles Pack [Published WSJ.com: What's News US - Jan 15 2013]
AstraZeneca Shakeup [Published In the Pipeline - Jan 15 2013]
Roche And AstraZeneca Overhaul R&D Operations [Published Pharmalot - Jan 15 2013]
AstraZeneca reports positive results of OSKIRA-... [Published PharmaBiz - Dec 14 2012]
AstraZeneca reports positive results from nalox... [Published PharmaBiz - Nov 15 2012]
MRC-AstraZeneca collaboration to benefit resear... [Published PharmaBiz - Nov 01 2012]
AstraZeneca gets European marketing nod for Zin... [Published PharmaBiz - Aug 29 2012]

Blogs

sort by: Date \| Relevance
How Will AstraZeneca Fare With These Losses? [Published Wall St. Cheat Sheet - Jan 15 2013] Britain’s second-largest pharmaceutical company, AstraZeneca ( NYSE:AZN ), will face its second large shake-up in two months, with the exit of two top officials from the company . Shake-up 1 AstraZeneca faced the first shake-up in early December ...
Pascal Soriot rings the changes in AZ [Published PharmaGossip - Jan 15 2013] AstraZeneca in new management shake-upBoth Martin Mackay, president of research and development, and Tony Zook, global commercial executive vice president, have had their roles "eliminated" and are to leave the company at the end of January.Under a significant ...
AstraZeneca Shakeup [Published In the Pipeline - Jan 15 2013] And while we're talking big pharma shakeups, I note that AstraZeneca's new CEO has rearranged the executive furniture pretty vigorously , ditching Martin Mackay. He was the R&D head, ex-Pfizer, and seems to have lasted about two years at AZ, whose well-known ...
Roche And AstraZeneca Overhaul R&D Operations [Published Pharmalot - Jan 15 2013] The meager pipelines and R&D setbacks plaguing the pharmaceutical industry have prompted two of the largest drugmakers to shake up their operations today. Roche hired John Reed (pictured left), who heads the Sanford-Burnham Medical Research Institute ...